2024
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
Lizama B, Williams C, North H, Pandey K, Duong D, Di V, Mecca A, Blennow K, Zetterberg H, Levey A, Grundman M, van Dyck C, Caggiano A, Seyfried N, Hamby M. CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease. Alzheimer's & Dementia 2024, 20: 6860-6880. PMID: 39166791, PMCID: PMC11485314, DOI: 10.1002/alz.14152.Peer-Reviewed Original ResearchVolumetric magnetic resonance imagingMagnetic resonance imagingPharmacodynamic biomarkersMeta-analysisClinical developmentCerebrospinal fluidPhase 2 clinical trialResonance imagingAlzheimer's diseaseMechanism of actionClinical trialsTandem mass tag-mass spectrometryClinical cohortMild to moderate ADCandidate biomarkersCT1812CohortBiomarker signaturesBiomarkersProteomic findingsUnbiased analysisNetwork analysisAmyloid-betaSynaptic biologyBiological impactA pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
van Dyck C, Mecca A, O’Dell R, Bartlett H, Diepenbrock N, Huang Y, Hamby M, Grundman M, Catalano S, Caggiano A, Carson R. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease. Alzheimer's Research & Therapy 2024, 16: 20. PMID: 38273408, PMCID: PMC10809445, DOI: 10.1186/s13195-024-01382-2.Peer-Reviewed Original ResearchConceptsMild to moderate dementiaPositron emission tomographyAlzheimer's diseaseVolumetric MRIModerate dementiaClinical rating scalesSynaptic vesicle glycoprotein 2ACerebrospinal fluidMouse model of ADPharmacodynamic effectsPlacebo-controlled phase 1 clinical trialBiomarkers of AD pathologyClinical trialsCognitive measuresNominally significant differencesPhase 1 clinical trialModel of ADHippocampal cortexPhase 1/2 studyRating ScaleParallel-group trialSynaptic densityTrial registrationThe clinical trialPlacebo-controlledSigma-2 receptor ligands
2011
Angiotensin(1–7) increases survival of stroke‐prone spontaneously hypertensive rats
Regenhardt R, Ritucci‐Chinni P, Desland F, Mecca A, Sumners C. Angiotensin(1–7) increases survival of stroke‐prone spontaneously hypertensive rats. The FASEB Journal 2011, 25: 650.10-650.10. DOI: 10.1096/fasebj.25.1_supplement.650.10.Peer-Reviewed Original ResearchHemorrhagic strokeCerebroprotective actionHypertensive ratsSystemic arterial pressureNovel therapeutic targetArtificial cerebrospinal fluidWeeks of ageAngiotensin systemIschemic strokeSalt dietArterial pressureSpontaneous hypertensionTherapeutic optionsAngiotensin IIINOS expressionStroke occurrenceCerebrospinal fluidTherapeutic targetOsmotic pumpHemorrhagic stroke occurrenceStrokeRatsSignificant increaseWeeksSurvival
2009
Cerebroprotective action of angiotensin 1‐7 in a rat model of ischemic stroke
Mecca A, O'Connor T, Dooies K, Katovich M, Sumners C. Cerebroprotective action of angiotensin 1‐7 in a rat model of ischemic stroke. The FASEB Journal 2009, 23: 947.1-947.1. DOI: 10.1096/fasebj.23.1_supplement.947.1.Peer-Reviewed Original ResearchMiddle cerebral artery occlusionAngiotensin-Converting Enzyme 2Ang-1Artificial cerebrospinal fluidControl ratsIschemic strokeNeurological deficitsInfarct sizeAngiotensin 1Rat modelArtificial cerebrospinal fluid controlsIpsilateral gray matterCerebral artery occlusionLateral ventricular cannulasConverting enzyme 2Cerebrospinal fluid controlsCerebroprotective propertiesMCAO inductionArtery occlusionCerebroprotective actionEndothelin-1Ventricular cannulaEnzyme 2Cerebrospinal fluidET-1